![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-1-full.png "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Anti-HER2 Agents Gain Ground in Colorectal Cancer
Cancers | Free Full-Text | Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book
Precision Cancer Medicines for Colon Cancer - CancerConnect
Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer | SpringerLink
HER2 Biomarker | Colorectal Cancer Alliance
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - ScienceDirect
Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI
HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti‐Epidermal Growth Factor Receptor Therapy | Semantic Scholar
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-5-2x.jpg "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
Q&A column - CAP TODAY
The HER family as therapeutic targets in colorectal cancer - ScienceDirect
Comprehensive assessment of HER2 alteration in a colorectal cancer coh | CMAR
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
HER2/neu testing in primary colorectal carcinoma | British Journal of Cancer
HER2 Biomarker | Colorectal Cancer Alliance
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
![PDF] Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/94e7ce3cbf29365fa3c4053b007a40513f46b3af/3-Figure1-1.png "PDF] Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status | Semantic Scholar")
PDF] Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status | Semantic Scholar
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer | BMC Cancer | Full Text
